PB1072 - Evaluation of the ultrasound sonorheometry based Quantra® System to monitor hemostasis in patients undergoing plasma exchange therapy

Tuesday, July 12, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Co-Author(s)

CW

Clementine Wahl

Assistant professor
Assistance Publique Hôpitaux de Paris
Paris, Ile-de-France, France
CC

Cécile Cornillot

Product Line Manager
Stago Biocare
Asnieres sur Seine, Ile-de-France, France
MM

Murielle Maison

Nurse
Assistance Publique Hôpitaux de Paris
Paris, Ile-de-France, France
LL

Laura Lhotellier

Nurse
Assistance Publique Hôpitaux de Paris
Paris, Ile-de-France, France
KY

Kelly Yangaju

Nurse
Assistance Publique Hôpitaux de Paris
Paris, Ile-de-France, France
MD

Mélanie Dalibard

Nurse
a
Paris, Ile-de-France, France
LM

Laure Macraigne

Resident
Assistance Publique Hôpitaux de Paris
Paris, Ile-de-France, France
VL

Vincenette Lopez

Resident
Assistance Publique Hôpitaux de Paris
Paris, Ile-de-France, France
AC

Alexandre Chhing

Resident
Assistance Publique Hôpitaux de Paris
Paris, Ile-de-France, France

Presenting Author(s)

Corinne Frere, MD, PhD

MD,PhD
AP.HP Sorbonne Université
Paris, Ile-de-France, France

Co-Author(s)

SS

Samir Saheb

Associate Professor
Assistance Publique Hôpitaux de Paris
Paris, Ile-de-France, France

Background: Plasma exchange therapy (PET) with albumin replacement results in coagulation factors and platelets depletion. A close and timely monitoring of hemostasis is therefore warranted before PET, particularly in patients at risk of bleeding or those planned to receive large volume exchanges. The Quantra® system is a coagulation POC device based on Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry equipped with a disposable QPlus® 4-channel cartridge that performs 4 independent measurements with different combination of reagents. The output test results include Clot Time (CT), Clot Stiffness (CS), Fibrinogen Contribution to Clot Stiffness (FCS) and Platelet Contribution to Clot Stiffness (PCS).

Aims: To compare the Quantra® QPlus® parameters to routine laboratory parameters for near-POC monitoring of hemostasis in patients undergoing PET.

Methods: This prospective, single-center, observational study was conducted in the apheresis unit of a tertiary care center hospital from December 2021 to January 2022. Blood sampling was performed just before PET. SEER Sonorheometry was performed on a Quantra® analyzer with the QPlus® Cartridge (Stago BioCare, Asnières, France). Activated Partial Thromboplastin Time (aPTT) and functional fibrinogen level were determined on a STA-R Max analyzer using commercially available reagents (Stago, Asnières, France). Platelet count was performed on a XN 9100 analyzer using the Cellpack reagent (Sysmex, Villepinte, France). Statistical analysis was performed using GraphPad Prism version 8.4.2 (GraphPad Software, La Jolla California USA).

Results: 33 patients were prospectively enrolled in the study. Significant correlations were observed between CT and aPTT (r=0.62, p=0.001), FCS and fibrinogen levels (r=0.85, p< 0.0001), CS and fibrinogen levels (r=0.85, p< 0.0001), and PCS and platelet count (r=0.71, p< 0.0001). Result delivery was much faster with the Quantra® analyzer compared to conventional tests (mean time 35 versus 74 minutes, p< 0.0001).

Conclusion(s): SEER sonorheometry demonstrates significant correlations with routine laboratory tests and provided prompt information to manage hemostasis in patients undergoing PET.